Empagliflozin Not Found to Preserve Exercise Ability in Chronic Heart Failure
Empagliflozin was not found to affect the exercise ability of patients with chronic heart failure with reduced or preserved ejection fraction after 12 weeks of treatment.
Empagliflozin was not found to affect the exercise ability of patients with chronic heart failure with reduced or preserved ejection fraction after 12 weeks of treatment.